Csenge Advisory Group Has $2.38 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Csenge Advisory Group raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 319.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,394 shares of the biopharmaceutical company’s stock after acquiring an additional 16,288 shares during the period. Csenge Advisory Group’s holdings in Gilead Sciences were worth $2,375,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. GoalVest Advisory LLC lifted its position in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the 3rd quarter worth about $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $27,000. Putney Financial Group LLC increased its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the period. Finally, Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the second quarter worth about $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 3.0%

GILD opened at $124.91 on Friday. Gilead Sciences, Inc. has a 1-year low of $91.68 and a 1-year high of $128.70. The stock has a market capitalization of $154.97 billion, a PE ratio of 19.37, a PEG ratio of 0.66 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm has a 50-day moving average price of $123.36 and a two-hundred day moving average price of $118.06.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares in the company, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 136,757 shares of company stock valued at $16,951,612 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GILD shares. Citigroup lifted their price objective on Gilead Sciences from $135.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. UBS Group reissued a “buy” rating on shares of Gilead Sciences in a report on Thursday. Finally, Mizuho boosted their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $133.16.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.